Kontrolsüz Warfarin Kullanımına Bağlı Gelişen Yaygın Alveoler Hemoraji: Olgu Sunumu

Akagün, Tülin; Güngör, Erdal; Akdogan, Elif; Bülbül, Yilmaz; Sönmez, Mehmet
September 2008
International Journal of Hematology & Oncology / UHOD: Uluslarar;Sep2008, Vol. 18 Issue 3, p170
Academic Journal
Warfarin; one of the most common oral anticoagülant drug is used for treatment of thromboembolic events and also for prevention of thromboembolic complications in atrial fibrillation and other cardiovascular diseases. The most important adverse effect is hemorrhage. Diffuse alveolar hemorrhage (DAH) is a rare complication of warfarin dependent hemorrhages. Nevertheless, it is a life-threatening disease if the treatment was not started as soon as possible. Our case represents DAH as a complication of uncontrolled warfarin therapy. We aimed to overview the diagnosis and treatment choices of DAH.


Related Articles

  • Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies. Fusaro, Maria; Crepaldi, Gaetano; Maggi, Stefania; D'Angelo, Angela; Calò, Lorenzo; Miozzo, Davide; Fornasieri, Alessandro; Gallieni, Maurizio // Current Vascular Pharmacology;Nov2011, Vol. 9 Issue 6, p763 

    Anticoagulant therapy in patients with atrial fibrillation requires careful evaluation because its benefits i.e. prevention of thromboembolism, must be greater than the risk of bleeding. Patients at higher risk of thrombosis are evaluated through specific scores, such as the CHA2DS2VASc, coupled...

  • LONG-TERM ANTICOAGULANT THERAPY AS AN OFFICE PROCEDURE. Markson, Victor I. // Angiology;Jan1964, Vol. 15 Issue 1, p51 

    1. The use of anticoagulant therapy for patients with thromboembolic disease on an outpatient basis is recorded for 144 cases followed from 3 months to 5 years using, as the anticoagulant of choice, warfarin sodium. 2. Safe, therapeutic prothrombin levels can be reached and maintained...

  • Identifying the Risks of Anticoagulation in Patients with Substance Abuse. Efird, Lydia; Miller, Donald; Ash, Arlene; Berlowitz, Dan; Ozonoff, Al; Zhao, Shibei; Reisman, Joel; Jasuja, Guneet; Rose, Adam // JGIM: Journal of General Internal Medicine;Oct2013, Vol. 28 Issue 10, p1333 

    BACKGROUND: Warfarin is effective in preventing thromboembolic events, but concerns exist regarding its use in patients with substance abuse. OBJECTIVE: Identify which patients with substance abuse who receive warfarin are at risk for poor outcomes. DESIGN: Retrospective cohort study. Diagnostic...

  • Warfarin.  // Reactions Weekly;6/1/2013, Issue 1455, p34 

    The article describes the case of a 68-year-old man who developed a perirenal haemorrhage while receiving treatment with anticoagulation and warfarin.

  • Acenocoumarol/warfarin.  // Reactions Weekly;9/7/2013, Issue 1468, p5 

    The article presents a case study of a 40-year-old woman who developed bleeding complications after administering anticoagulation with acenocoumarol and warfarin.

  • Prophylactic Anticoagulant Therapy in the Orthopedic Patient. Neu Jr., Leo T.; Waterfield, Jim R.; Ash, Charles J. // Annals of Internal Medicine;Mar65, Vol. 62 Issue 3, p463 

    Focuses on a study of orthopedic patients who suffered trauma of the pelvis and lower extremities, to determine the value of routine prophylactic warfarin sodium anticoagulation in the prevention of thromboembolic phenomena. Significance of the variation between anticoagulated patients from the...

  • Anticoagulation reduces cancer risk after thromboembolism.  // Geriatrics;Sep2000, Vol. 55 Issue 9, p93 

    Presents an abstract of the study `Incidence of Cancer After Prophylaxis With Warfarin Against Recurrent Venous Thromboembolism,' by S. Schulman and P. Lindmarker, which appeared in the June 2000 issue of the `New England Journal of Medicine.'

  • An overview of antithrombotic therapy. Blann, Andrew D; Landray, Martin J; Lip, Gregory Y H // BMJ: British Medical Journal (International Edition);10/5/2002, Vol. 325 Issue 7367, p762 

    Provides an overview of antithrombotic therapy. Clinical problems relating to thrombosis; Cardiovascular disorders associated with it; Factors that influence the efficacy of warfarin; Efficiency of hirduin and direct thrombin inhibitors. INSETS: Contraindications to aspririn;Factors that...

  • The relationship between CYP2C9 gene polymorphisms and upper gastrointestinal bleeding in patients who used warfarin. Ucar, Mahmut; Alagozlu, Hakan; Sahin, Safak; Ozdemir, Ozturk // Medicinski Glasnik;Feb2013, Vol. 10 Issue 1, p50 

    Aim Oral anticoagulants are the most common used substance for treatment and prophylaxis of warfarin venous and arterial thromboembolic disorders in the world. Therapeutic index of warfarin is narrow. CYP2C9 is a hepatic microsomal enzyme and has a primary role in metabolism of warfarin and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics